Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
利菲卢塞（一种一次性自体肿瘤浸润淋巴细胞 (TIL) 疗法）在免疫检查点抑制剂和靶向治疗后进展的晚期黑色素瘤患者中的疗效和安全性：C-144-01 研究连续队列的汇总分析
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2022-005755
Chesney, Jason; Lewis, Karl D; Kluger, Harriet; Hamid, Omid; Whitman, Eric; Thomas, Sajeve; Wermke, Martin; Cusnir, Mike; Domingo-Musibay, Evidio; Phan, Giao Q; Kirkwood, John M; Hassel, Jessica C; Orloff, Marlana; Larkin, James; Weber, Jeffrey; Furness, Andrew J S; Khushalani, Nikhil I; Medina, Theresa; Egger, Michael E; Graf Finckenstein, Friedrich; Jagasia, Madan; Hari, Parameswaran; Sulur, Giri; Shi, Wen; Wu, Xiao; Sarnaik, Amod
